GET DAILY SIGNALSAlector (ALEC): Can the Stock Reach Its $3.90 Analyst Target for an +88% Gain?
Key Takeaways
- The $3.90 consensus target represents the average of five current analyst price targets, which range from a low of $1.00 to a high of $8.00.
- Trading near $2.07, the shares would need to rise roughly 88% to hit that average target, a substantial move by any measure.
- Analyst opinions remain sharply divided, with Buy-rated firms highlighting the platform’s potential and Sell-rated firms pointing to ongoing cash burn and an early-stage pipeline.
- The Genentech licensing deal for the AL050 Parkinson’s program provides up to about $1.27 billion in potential value and extends the cash runway into 2029.
- Key risks include prior late-stage trial setbacks, continued cash consumption, and a pipeline with few near-term catalysts.
- Additional details on the ticker are available via its Major News, Today’s Price Move, Forecast, and Earnings pages.
What the Analysts Are Saying
Five current analyst targets were examined. The most optimistic comes from H.C. Wainwright at $8.00 (Buy, raised from $5.00 in mid-October 2026), which frames Alector as a platform company rather than a single-asset story. BTIG also maintains a Buy rating with a $6.00 target. On the more cautious side, Bank of America Securities has a Sell rating and $1.00 target, Morgan Stanley carries an Underweight rating with a $3.00 target, and Mizuho Securities holds a Hold rating with a $1.50 target. The overall range spans $1.00 to $8.00, producing a mean of $3.90. This spread reflects real differences in how the pipeline is being valued, with bulls focusing on external validation of the ABC platform and bears emphasizing cash runway and early-stage status. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Position and the Road to the Target
Alector shares have moved within a 52-week range of roughly $1.09 to $2.76. After the early-October 2026 Genentech licensing announcement the stock re-rated higher before settling, recently trading near $2.07. Reaching $3.90 would require an increase of about 88%, pushing the shares well above the 52-week high of $2.76 and into levels not seen since before the 2024–2025 pipeline disappointments.
Potential Positive Drivers
The most concrete catalyst remains the global license agreement with Genentech, a Roche unit, for AL050, a brain-penetrant GCase enzyme replacement therapy for Parkinson’s disease. The deal includes a $100 million upfront payment, up to $1.17 billion in milestones, and tiered royalties. Management indicated the agreement extends the cash runway into 2029, lowering near-term dilution risk and supporting wholly owned programs. Further support could come from progress on AL137, the anti-amyloid-beta antibody for Alzheimer’s, and continued validation of the ABC platform across different modalities.
Risks That Could Limit Upside
Execution risk remains the primary concern. Alector has already seen the failure of latozinemab (AL001) in a Phase 3 frontotemporal dementia trial, a Phase 2 miss for AL002 in Alzheimer’s, and a setback for AL101 that contributed to a roughly 49% workforce reduction. The remaining pipeline is largely early-stage with limited near-term data readouts, and the company continues to use cash even after the Genentech transaction. Cautious analysts view the deal mainly as a runway extension rather than a signal of long-term equity upside, and any further clinical disappointment could pressure the valuation.
Technical Levels and Market Structure
The 52-week high near $2.76 serves as the key near-term resistance; a sustained move above it would be needed before the $3.90 target comes into clearer view. The $3.00 level also carries psychological weight given Morgan Stanley’s target. On the downside, the $1.50 to $1.83 zone has provided support in recent pullbacks, while the 52-week low near $1.09 marks the broader reference point.
What Investors Should Watch
Analyst targets generally reflect a 12-month horizon. Key items to monitor include upcoming earnings and guidance, any analyst revisions after new data, clinical progress on AL137 and the ABC platform, and whether additional milestone payments from the Genentech collaboration are realized. Regulatory developments and overall biotech-sector sentiment also matter given the stock’s sensitivity to financing conditions and binary clinical outcomes. From what I see, tracking these factors alongside technical signals helps form a more complete picture.
How Tickeron’s AI Daily Buy/Sell Signals Fit Into My Process
In my research I occasionally reference Tickeron’s AI Daily Buy/Sell Signals to monitor momentum shifts in volatile names like this one. The system continuously scans thousands of stocks and ETFs to generate Buy, Sell, or Hold signals based on technical behavior and AI-driven analysis, which can complement the fundamental review when evaluating potential moves toward analyst targets.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALEC sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for ALEC moved above the 200-day moving average on September 28, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +7.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALEC advanced for three days, in 217 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALEC as a result. In 88 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for ALEC turned negative on October 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 35 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
ALEC moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALEC crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for ALEC entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-23.519) is normal, around the industry mean (3.037). P/E Ratio (-1.927) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (15.060) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating steady price growth. ALEC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics for Alzheimer's disease and other neurodegenerative disorders
Industry Biotechnology
Advertisement